Peer-Reviewed Publication
JAMIA Open2025;8(4):ooaf069.August 1, 2025Journal Article
Utilizing Immuno-Oncology registry data for enhanced non-small cell lung cancer treatment predictions.
Yili Zhang1, Shaked Lev-Ari2, Jacob Zaemes3, Alexandra Della Pia4, Bianca DeAgresta4, Samir Gupta1, Alex Marki5, Rachel Zemel5, Andrew Ip4, Adil Alaoui1, Charalampos Charalampous5, Iris Rahman6, Olivia Wilkins5, Subha Madhavan1,7, Peter McGarvey1, Lauren Pascual4, Michael B Atkins8, Neil J Shah9
1Innovation Center for Biomedical Informatics, Georgetown University, Washington, DC, 20007, United States.
2Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center at Tel Hashomer, Ramat Gan, 526260, Israel.
3Harvard Medical Faculty Physicians, Beth Israel Deaconess Medical Center Inc, Boston, MA, 02215, United States.
4John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ, 07061, United States.
5MedStar Georgetown University Hospital, Washington, DC, 20007, United States.
6MedStar Washington Hospital Center, Washington, DC, 20010, United States.
7Pfizer Research and Development, New York, NY, 11206, United States.
8Georgetown-Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC, 20007, United States.
9Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, United States.
Abstract
OBJECTIVES: We aim to leverage more comprehensive phenotypic and genotypic clinical data to enhance the treatment response predictions.
MATERIALS AND METHODS: The study cohort includes 213 NSCLC patients who underwent ICI therapy. Patients were categorized based on treatment outcomes: those with complete or partial responses were considered responders, while those exhibiting stable or progressive…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans